Department of Urology, Ulm University Medical Center, Prittwitzstrasse 43, D-89075 Ulm, Germany.
World J Surg Oncol. 2011 Oct 12;9:126. doi: 10.1186/1477-7819-9-126.
Whenever technically feasible and oncologically justified, nephron-sparing surgery is the current standard of care for localized renal cell carcinomas (RCC). The main complications of partial nephrectomy, especially for large and centrally located tumors, are urinary leakage and parenchymal bleeding. We prospectively evaluated the pros and cons of using porcine small intestinal submucosa (SIS, Surgisis®) to close the renal defect after nephron-sparing surgery.
We used Surgisis® (Cook medical, Bloomington, IN, USA) to secure and compress the capsular defect after tumor resection in 123 patients submitted to 129 partial nephrectomies between August 2003 and February 2011.
The median tumor size was 3.7 cm (range 1.1-13.0 cm). Procedures were performed with cold ischemia in 24 cases (18.2%), with warm ischemia in 46 (35.6%), and without ischemia in 59 cases (44.8%). In the total group of patients, 4 (3.1%) developed urinary fistula, and only 2 (1.6%) required postoperative transfusions due to hemorrhage after the application of the small intestinal submucosa membrane.
Small intestinal submucosa is an easy-to-use biomaterial for preventing complications such as postoperative bleeding and urinary fistula in nephron-sparing surgery, especially in cases where tumor excision causes significant renal capsular and/or renal pelvic defects.
只要技术可行且符合肿瘤学要求,保留肾单位手术就是局限性肾细胞癌(RCC)的当前治疗标准。部分肾切除术的主要并发症,特别是对于大且位于中央的肿瘤,是尿漏和实质出血。我们前瞻性地评估了使用猪小肠黏膜下层(SIS,Surgisis®)来闭合保肾手术后肾缺损的优缺点。
我们在 2003 年 8 月至 2011 年 2 月期间对 123 例患者的 129 例部分肾切除术使用 Surgisis®(库克医疗,印第安纳州布卢明顿)来固定和压缩肿瘤切除后的包膜缺损。
肿瘤大小中位数为 3.7cm(范围 1.1-13.0cm)。24 例(18.2%)采用冷缺血,46 例(35.6%)采用热缺血,59 例(44.8%)不采用缺血。在所有患者中,有 4 例(3.1%)发生尿瘘,仅 2 例(1.6%)因应用小肠黏膜下层膜后出血而需要术后输血。
小肠黏膜下层是一种易于使用的生物材料,可预防保肾手术后出血和尿瘘等并发症,特别是在肿瘤切除导致明显的肾包膜和/或肾盂缺损的情况下。